Saikosaponin a Enhances Docetaxel Efficacy by Selectively Inducing Death of Dormant Prostate Cancer Cells through Excessive Autophagy

Saikosaponin A (SSA) was posed as a novel quiescent cancer cell (QCC)-eradicating agent by aggravating autophagy in QCCs. In combination with the current therapy, SSA had potential to improve treatment effectiveness and to prevent cancer recurrence.